We aim to elevate regenerative
medicine to the next level!
The Target Cells team is developing a novel, research-grade, commercial stem cell binding assay that mimics the targeted delivery of human stem cells for tissue and organ repair, particularly for heart regeneration
ABOUT US
Target Cells is a biotech start-up founded in 2023 by scientists from Poland and the USA specializing in stem cell research and cardiac regeneration.
Our goal is the comprehensive development of regenerative medicine applications for targeted stem cell-based products for myocardial repair.
We aim to commercialize products which will enable the evaluation of the efficacy of targeted stem cell delivery to selected human tissues under in vitro assay conditions, thereby reducing the cost, time and number of animals used in animal testing and advancing the development of targeted regenerative therapies.
The solutions we propose are addressed to scientific institutions and commercial entities, and in the long run also to medical centers whose area of operation is regenerative medicine.
MEET OUR TEAM
Catherine A. Phillips, PhD
Co-founder
Scientific consultant of TC Poland
Expert on stem cells
Read more
Robin McWherter, CMRT
Co-founder
Scientific consultant of TC Poland
Expert in the development of clinical products and cell labeling
Read more
Douglad D. Held, PhD
Scientific consultant of TC Poland
Expert on product development
Read more
PROJECTS
We are working on the validation of the innovative CardioBind test, designed to assess the
stability, specificity, and molecular composition of stem cell binding to heart tissues under in vitro conditions.
The project focuses on developing a tool to support personalized medicine and is being
implemented in cooperation with the Jagiellonian University.
The research and development work is carried out under the European Funds for
Małopolska 2021-2027 program (Measure 1.2 Innovation Vouchers for SMEs).
The completion of the project is scheduled for April 2026.
We are developing a plate-based assay that evaluates the ability of selected types of human stem cells to bind to cardiac tissue under in vitro conditions.
The project is part of the BRIdge Alpha program of the Polish National Center for Research and Development..
Completion of R&D is scheduled for December 2023, and commercialization of the test will take place in 2024.
OUR INVESTORS
OUR PARTNERS
